Use of trinucleotide repeat RNAs to treat cancer
US12281310B2 · kind B2 · utility
0Cited by
2References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2021 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Sep 10, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.